Get the Stockscreener App
65.93
0.78%
0.49
Cytokinetics Inc stock is traded at $65.93, with a volume of 284.37K.
It is up +0.78% in the last 24 hours and up +14.04% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$65.44
Open:
$65.5
24h Volume:
284.37K
Relative Volume:
0.12
Market Cap:
$8.06B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-12.53
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-1.49%
1M Performance:
+14.04%
6M Performance:
+115.95%
1Y Performance:
+34.32%
1-Day Range:
$64.80
$66.14
1-Week Range:
$62.86
$67.80
52-Week Range:
$29.31
$67.98
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
65.95 | 8.00B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.72 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.66 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.99 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
905.38 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.66 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Cytokinetics, Incorporated $CYTK Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS - Defense World
Cytokinetics Shares Face Critical FDA Verdict - Ad-hoc-news.de
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Ready to Jump After Recent Trade: Cytokinetics Inc (CYTK) - Setenews
Rep. Gilbert Ray Cisneros, Jr. Buys Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World
How Cytokinetics Incorporated (KK3A) stock trades under stagflationWeekly Gains Report & Safe Capital Growth Trade Ideas - newser.com
What macro factors could drive Cytokinetics Incorporated (KK3A) stock higherJuly 2025 Action & Weekly Watchlist for Hot Stocks - newser.com
Insider Sell: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Is Cytokinetics Incorporated (KK3A) stock trading at attractive multiplesJuly 2025 Trade Ideas & Safe Entry Point Alerts - newser.com
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics Director Sells 5,000 Shares - TradingView
Dir Parshall Sells 5,000 ($323.7K) Of Cytokinetics Inc [CYTK] - TradingView
What market sentiment indicators show for Cytokinetics Incorporated (KK3A) stock2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea ... - Bluefield Daily Telegraph
Will Cytokinetics Incorporated (KK3A) stock draw ESG focused funds - newser.com
Cytokinetics Inc (KK3A.HM) Stock Historical Prices & Data - Yahoo! Finance Canada
Cytokinetics Inc (KK3A.HM) Latest Stock News & Headlines - Yahoo! Finance Canada
Cytokinetics Inc (KK3A.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insider Sell Alert: Fady Malik Sells 2,200 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Cytokinetics Executive Sells Shares - TradingView
Cytokinetics Grants Stock Options and RSUs to New Executive and Employees as Inducements to Employment - Quiver Quantitative
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
What Does the Market Think About Cytokinetics Inc? - Benzinga
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); enCore Energy ... - Bluefield Daily Telegraph
Cytokinetics Incorporated (CYTK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Urgently Reminds Investors of - GlobeNewswire
Total debt per share of Cytokinetics, Incorporated – DUS:KK3A - TradingView
Recover Investment Losses: Class Action Initiated Against Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
Cytokinetics at Jefferies London: Aficamten’s Strategic Path Forward By Investing.com - Investing.com Canada
Cytokinetics at Jefferies London: Aficamten’s Strategic Path Forward - Investing.com India
CYTK FINAL DEADLINE: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit - Business Wire
Cytokinetics at Jefferies London: Aficamten's Strategic Path Forward - Investing.com
Cytokinetics at Jefferies London: Aficamten's Strategic Path Forward By Investing.com - Investing.com Nigeria
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated Investors - GlobeNewswire
Securities Lawsuit Alert: Cytokinetics, Incorporated (CYTK) InvestorsContact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
Former Exelixis GC Named Legal Chief At Cytokinetics - Law360
Cytokinetics (CYTK) Supports American Heart Association Initiati - GuruFocus
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders - MarketScreener
Cytokinetics supports American Heart Association initiative to improve care for people living with hypertrophic cardiomyopathy - MarketScreener
Cytokinetics Supports American Heart Association Initiative to Enhance Care for Hypertrophic Cardiomyopathy Patients - Quiver Quantitative
Cytokinetics (Nasdaq: CYTK) backs AHA effort to expand HCM registry, reduce underdiagnosis - Stock Titan
Cytokinetics Shares Surge Amid Legal Challenges and Clinical Promise - Ad-hoc-news.de
Imbria Pharmaceuticals, Inc. announced that it has received funding from a group of investors - MarketScreener
Cytokinetics 24 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Cytokinetics, IncorporatedCYTK - Louisiana First News
November 17, 2025 Deadline: Join Class Action Lawsuit Against Cytokinetics, Incorporated (CYTK)Contact Levi & Korsinsky - ACCESS Newswire
Key facts: Cytokinetics stock drops 12.98%; class action lawsuit filed - TradingView
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):